Dosage, titration, and gaps in treatment with extended release niacin in clinical practice

2008 ◽  
Vol 24 (6) ◽  
pp. 1817-1821 ◽  
Author(s):  
Sachin J. Kamal-Bahl ◽  
Thomas A. Burke ◽  
Douglas J. Watson ◽  
Charles E. Wentworth
Keyword(s):  
Clinical Practice ◽  
Extended Release ◽  
Dosage Titration

Extended-release niacin/laropiprant for lipid management: observational study in clinical practice

2013 ◽  
Vol 67 (6) ◽  
pp. 527-535 ◽  
Author(s):  
E. Steinhagen-Thiessen ◽  
W. Dänschel ◽  
C. Buffleben ◽  
W. Smolka ◽  
D. Pittrow ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Observational Study ◽  
Extended Release ◽  
Lipid Management

Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry

Addiction ◽  
2018 ◽  
Vol 113 (8) ◽  
pp. 1477-1487 ◽  
Author(s):  
Andrew J. Saxon ◽  
Sarah C. Akerman ◽  
Chih-Chin Liu ◽  
Maria A. Sullivan ◽  
Bernard L. Silverman ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Treatment Outcomes ◽  
Extended Release ◽  
Opioid Use Disorder ◽  
Opioid Use

Determinants of lipid goal achievement in patients on extended-release nicotinic acid/laropiprant in primary care clinical practice

2012 ◽  
Vol 29 (1) ◽  
pp. 33-40 ◽  
Author(s):  
Wilfried Dänschel ◽  
Elisabeth Steinhagen-Thiessen ◽  
Claudia Buffleben ◽  
David Pittrow ◽  
Steven K. Hildemann
Keyword(s):  
Primary Care ◽  
Clinical Practice ◽  
Nicotinic Acid ◽  
Extended Release ◽  
Goal Achievement

scholarly journals A retrospective medical chart review of clinical outcomes in children and adolescents with attention-deficit/hyperactivity disorder treated with guanfacine extended-release in routine Canadian clinical practice

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Judy van Stralen ◽  
Simerpal K. Gill ◽  
Christopher J. Reaume ◽  
Kenneth Handelman
Keyword(s):  
Clinical Practice ◽  
Children And Adolescents ◽  
Clinical Outcomes ◽  
School Performance ◽  
Adjunctive Therapy ◽  
Chart Review ◽  
Extended Release ◽  
Adhd Symptoms ◽  
Home Life ◽  
Hyperactivity Disorder

Abstract Objective This study evaluated clinical outcomes in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) treated with the α2-adrenoceptor agonist guanfacine extended-release (GXR) in routine Canadian clinical practice. Methods This retrospective chart review focused on patients with ADHD aged 6–17 years initiating treatment with GXR as monotherapy or adjunctive therapy. Patients were followed for up to 12 months after GXR initiation and, if they had received prior ADHD pharmacotherapy, for 12 months before GXR initiation. The primary outcome was change in ADHD symptoms and functionality based on physician assessments, classified as improvement, no change, or worsening relative to the time of GXR initiation. Treatment-emergent adverse events (TEAEs) were evaluated. Clinical outcomes were also analyzed post hoc according to whether GXR treatment was received as monotherapy or adjunctive therapy, and by select psychiatric comorbidities. Exploratory analyses were conducted in patients who had received prior ADHD pharmacotherapy to evaluate clinical outcomes after initiating GXR. Results Improvements in ADHD symptoms were reported for 232/330 (70.3%) patients. Functional improvements in school performance and home life were reported for 213/330 (64.5%) and 209/330 (63.3%) patients, respectively. The most frequent TEAEs (≥ 5%) were somnolence, headache, insomnia, presyncope, and decreased appetite. Improvements in ADHD symptoms were observed when GXR was received as either monotherapy (35/60 [58.3%]) or adjunctive therapy (197/270 [73.0%]). Improvements in ADHD symptoms and functionality were observed in the majority of patients with select psychiatric comorbidities. Among patients who had experienced worsening of symptoms with prior ADHD pharmacotherapy, 44/54 (81.5%) experienced symptom improvement, 33/44 (75.0%) who had previously experienced worsening of school performance improved, and 34/48 (70.8%) who had previously experienced worsening of home life improved. Conclusion In Canadian routine clinical practice, most children and adolescents with ADHD treated with GXR experienced improvements in ADHD symptoms and in functionality both at school and at home.

Use of extended-release niacin in clinical practice

2008 ◽  
Vol 3 (1) ◽  
pp. 9-16 ◽  
Author(s):  
Ramya S Suryadevara ◽  
Richard H Karas ◽  
Jeffrey T Kuvin
Keyword(s):  
Clinical Practice ◽  
Extended Release

scholarly journals Optimizing extended-release carbidopa/levodopa in Parkinson disease

2016 ◽  
Vol 7 (1) ◽  
pp. 86-93 ◽  
Author(s):  
Alberto J. Espay ◽  
Fernando L. Pagan ◽  
Benjamin L. Walter ◽  
John C. Morgan ◽  
Lawrence W. Elmer ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Parkinson Disease ◽  
Extended Release ◽  
Low Dose ◽  
Immediate Release ◽  
Motor Complications ◽  
Release Formulation ◽  
Extended Release Formulation ◽  
Dosing Frequency ◽  
Wearing Off

AbstractPurpose of review:To help clinicians optimize the conversion of a patient's Parkinson disease pharmacotherapy from immediate-release carbidopa/levodopa (IR CD/LD) to an extended-release formulation (ER CD/LD).Recent findings:Eleven movement disorders specialists achieved consensus positions on the modification of trial-based conversion guidelines to suit individual patients in clinical practice.Summary:Because the pharmacokinetics of ER CD/LD differ from those of IR CD/LD, modification of dosage and dosing frequency are to be expected. Initial regimens may be based on doubling the patient's preconversion levodopa daily dosage and choosing a division of doses to address the patient's motor complications, e.g., wearing-off (warranting a relatively high ER CD/LD dose, possibly at a lower frequency than for IR CD/LD) or dyskinesia (warranting a relatively low dose, perhaps at an unchanged frequency). Patients should know that the main goal of conversion is a steadier levodopa clinical response, even if dosing frequency is unchanged.

Poster 339 Dosage Titration of Oxymorphone Extended Release for Relief of Chronic Low Back Pain in Patients With Comorbidities

PM&R ◽  
2011 ◽  
Vol 3 ◽  
pp. S290-S291
Author(s):  
John H. Peniston ◽  
Errol Gould ◽  
Matthew S. Wieman ◽  
Qinfang Xiang
Keyword(s):  
Low Back Pain ◽  
Back Pain ◽  
Chronic Low Back Pain ◽  
Extended Release ◽  
Low Back ◽  
Dosage Titration
Sign in / Sign up

Export Citation Format

Share Document